Ignite Creation Date:
2024-05-06 @ 4:35 PM
Last Modification Date:
2024-10-26 @ 2:13 PM
Study NCT ID:
NCT05033756
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-05-07
First Post:
2021-04-03
Brief Title:
Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency COMPRENDO
Sponsor:
Institut fuer Frauengesundheit
Organization:
Institut fuer Frauengesundheit
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-07-30
Start Date Type:
ACTUAL
Primary Completion Date:
2025-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-02
Completion Date Type:
ESTIMATED
First Submit Date:
2021-04-03
First Submit QC Date:
August 30 2021
Study First Post Date:
2021-09-05
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-05-06
Last Update Post Date:
2024-05-07
Last Update Post Date Type:
ACTUAL